A mosquito-borne viral infection spreading in the Americas and Europe, caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. As of 2017, there have been more than one million reported cases in the Americas and the economic impact is significant (e.g. Colombia outbreak 2014: $73.6m1).
About VLA1553
- VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya.
- VLA1553 was granted Fast Track designation by the FDA in December 20181.
- Valneva reported excellent final Phase 1 results for VLA1553 in November 20192.
- Valneva successfully completed an End-of-Phase 2 meeting with the FDA and agreed on the clinical development plan towards licensure3.
- Valneva expects to initiate the study as soon as the COVID-19 situation permits. Currently, the company assumes that Phase 3 can be initiated in the fourth quarter of this year.
Additional information about chikungunya:
- Valneva press release: http://valneva.com/press-release/valneva-awarded-fda-fast-track-designation-for-chikungunya-vaccine-candidate/
- Valneva press release: https://valneva.com/press-release/valneva-reports-excellent-final-phase-1-results-for-its-chikungunya-vaccine-candidate-confirms-plans/
- Valneva press release: https://valneva.com/press-release/valneva-reports-positive-end-of-phase-2-chikungunya-meeting-with-the-u-s-fda-sets-stage-for-phase-3-study/